Trial Profile
A Pilot, Phase 2a, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety and Tolerability, Efficacy, and Pharmacokinetics of AD-35 in Subjects With Mild to Moderate Alzheimer's Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2022
Price :
$35
*
At a glance
- Drugs AD-35 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms ROAD
- Sponsors Zhejiang Hisun Pharmaceutical
- 23 Mar 2020 Planned number of patients changed from 88 to 55.
- 23 Mar 2020 Planned End Date changed from 31 Jul 2020 to 31 Dec 2020.
- 23 Mar 2020 Planned primary completion date changed from 31 Jul 2019 to 1 Dec 2020.